Tocilizumab, humanized anti-IL-6 receptor (IL-6R) monoclonal antibody, is highly efficacious for the treatment of intractable autoimmune inflammatory diseases, including RA and juvenile idiopathic arthritis (JIA) in clinical trials [70]. The gene discussed is IL6R; the disease is juvenile idiopathic arthritis.